Abstract
In a phase I study, Gilead Sciences' PI3K-δ inhibitor idelalisib produced rapid tumor shrinkage-a response that lasted for 17 months on average-in about half of the 54 patients with chronic lymphocytic leukemia who participated.
MeSH terms
-
Clinical Trials, Phase I as Topic
-
Disease-Free Survival
-
Drug-Related Side Effects and Adverse Reactions
-
Humans
-
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
-
Leukemia, Lymphocytic, Chronic, B-Cell / genetics
-
Leukemia, Lymphocytic, Chronic, B-Cell / pathology
-
Phosphatidylinositol 3-Kinases / genetics
-
Phosphoinositide-3 Kinase Inhibitors
-
Protein Kinase Inhibitors / administration & dosage*
-
Purines / administration & dosage*
-
Purines / adverse effects
-
Quinazolinones / administration & dosage*
-
Quinazolinones / adverse effects
Substances
-
Phosphoinositide-3 Kinase Inhibitors
-
Protein Kinase Inhibitors
-
Purines
-
Quinazolinones
-
idelalisib